Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy
JAMA Network Open · 2026
DOI: 10.1001/jamanetworkopen.2026.22966 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Network Open, 2026. Verfasst von Annalise E Miner und 30 weiteren Autor:innen. Beteiligte Einrichtung: Boston University CTE Center and Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachuset…. Hauptthemen laut MEDLINE: Chronic Traumatic Encephalopathy, tau Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
Importance In vivo biomarkers for detecting neuropathologies from repetitive head impacts (RHI), including chronic traumatic encephalopathy (CTE), are needed.
Objective
To evaluate the utility of plasma phosphorylated tau 217 (p-tau217), assess its performance as a beta-amyloid (Aβ) biomarker in participants with RHI exposure at risk for CTE, and explore concordance with CTE neuropathology in a postmortem subsample. Design, Setting, and Participants This longitudinal, multicenter, case-control study used data from the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of CTE (DIAGNOSE CTE) Research Project, collected from September 2016 to October 2023. Participants were former American football players (case participants) and asymptomatic men unexposed to RHI (control participants). A subsample had available neuropathologic data. Exposures RHI, traumatic encephalopathy syndrome (TES) diagnoses, and levels of CTE certainty. Main Outcomes and Measures Plasma p-tau217 (classified as positive [≥0.63 pg/mL], intermediate [0.40-0.62 pg/mL], and negative [<0.40 pg/mL]), Aβ–positron emission tomography (PET; 18 F-florbetapir; with Aβ-positive defined as a standardized uptake value ratio [SUVR] ≥1.10), and tau-PET ( 18 F-flortaucipir). TES diagnoses were assigned by multidisciplinary consensus conference. Analyses of postmortem brains controlled for age, race, and APOE ε4 status.
Results
Among 231 participants (mean [SD] age, 57.75 [8.25] years), 177 were former football players (117 professional and 60 college) and 54 were unexposed participants. Former football players had higher baseline mean (SD) p-tau217 concentrations than unexposed participants (0.35 [0.26] pg/mL vs 0.27 [0.14] pg/mL; P = .008), although this was driven by a higher proportion of Aβ-PET–positive participants among former players. Plasma p-tau217 increased over time across the sample (B = 0.207 [95% CI, 0.117-0.298]; P < .001), with no significant time × exposure group interactions. Among football players, p-tau217 showed no time × group interactions with TES diagnosis, TES-CTE certainty, or RHI metrics. Higher p-tau217 concentration correlated with higher global Aβ-PET SUVR (B = 0.058 [95% CI, 0.053-3.501; P = .01), with a few discordant cases (5 participants were p-tau217–negative and Aβ-PET–positive; 7 participants were p-tau217–positive and Aβ-PET–negative). P-tau217 had similar areas under the curve for projecting Aβ-PET positivity as cerebrospinal fluid (CSF) p-tau181/Aβ42 and CSF Aβ40/42 measures (p-tau217: AUC, 0.88 [95% CI, 0.80-0.96]; CSF p-tau181/Aβ42: AUC, 0.89 [95% CI, 0.79-1.00]; CSF Aβ40/42: AUC, 0.85 [95% CI, 0.72-0.98]). Among 9 brain donors, 6 had CTE (stages II-IV; none with Alzheimer disease). Seven had negative or intermediate p-tau217, concordant with Aβ-PET. Two p-tau217 outliers with stage III CTE had normal concentrations upon additional testing. Conclusions and Relevance The findings of this study suggest that plasma p-tau217 concentration is unlikely to be useful for the detection of CTE, but it does show utility for ruling out Aβ pathology in participants at risk for CTE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Boston University CTE Center and Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
- Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
- UK Dementia Research Institute at UCL, London, United Kingdom.
- Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.
Förderung
- NIA NIH HHS
Zitieren
APA
Miner, A. E., Zetterberg, H., Blennow, K., Groh, J. R., Singh, A., Dieckhoff, K., Tripodis, Y., Adler, C. H., Balcer, L. J., Bernick, C., Peskind, E., Asken, B. M., Tanner, J. A., Rabinovici, G. D., Banks, S. J., Barr, W. B., Wethe, J. V., Cantu, R. C., Dodick, D. W., …, & DIAGNOSE CTE Research Project (2026). Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.22966
Vancouver
Miner AE, Zetterberg H, Blennow K, Groh JR, Singh A, Dieckhoff K, et al. Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.22966
BibTeX
@article{Miner2026,
author = {Miner, Annalise E and Zetterberg, Henrik and Blennow, Kaj and Groh, Jenna R and Singh, Alpana and Dieckhoff, Kari and Tripodis, Yorghos and Adler, Charles H and Balcer, Laura J and Bernick, Charles and Peskind, Elaine and Asken, Breton M and Tanner, Jeremy A and Rabinovici, Gil D and Banks, Sarah J and Barr, William B and Wethe, Jennifer V and Cantu, Robert C and Dodick, David W and Mez, Jesse and Palmisano, Joseph N and Martin, Brett and Stein, Thor D and McKee, Ann C and Cummings, Jeffrey L and Shenton, Martha E and Reiman, Eric M and Stern, Robert A and Ashton, Nicholas J and Alosco, Michael L and DIAGNOSE CTE Research Project, DIAGNOSE CTE Research Project},
title = {Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy},
journal = {JAMA Network Open},
year = {2026},
doi = {10.1001/jamanetworkopen.2026.22966}
}
EUVIMED